Gitnux/Report 2026

Ivd Diagnostics Industry Statistics

The global in vitro diagnostics (IVD) market is forecast to reach $153.7 billion by 2032, a sharp jump that follows a projected 12.6% CAGR from 2024 to 2032 and puts 2023 growth into sharper focus. Alongside the shifting demand signals from COVID-19 IVD to molecular diagnostics, this page also maps the regulatory and quality rules that determine what gets cleared, reimbursed, and scaled in the lab market.
93Statistics
52Sources
4Sections
10mRead
June 22, 2026Updated
Ivd Diagnostics Industry Statistics
Gabrielle FontaineWritten by Gabrielle Fontaine·Edited by Marcus Engström·Fact-checked by Abigail Foster
Published ·Updated
How this report is researched
01Editorial Scope

Before any source is gathered, an editor locks the question, what qualifies, and how the piece will be judged.

02Source Research

Search agents collect the source set and pull each data point out with its provenance attached.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 43 days
The global in vitro diagnostics market is projected to reach $153.7 billion by 2032, growing at a 12.6% CAGR from 2024 to 2032. Earlier estimates place the market at $73.2 billion in 2023, and COVID-era demand is forecast to reach $10.5 billion by 2026. This article connects market expansion with regulation and lab performance data to separate durable growth from short term shifts.

Key Takeaways

  • 12.6% CAGR projected for the global in vitro diagnostics (IVD) market from 2024 to 2032
  • $73.2 billion estimated global in vitro diagnostics (IVD) market size in 2023
  • $153.7 billion forecast global in vitro diagnostics (IVD) market size by 2032
  • FDA classifies in vitro diagnostic products into Class I, II, and III risk categories under 21 CFR Part 809
  • 21 CFR Part 807 requires device establishment registration and product listing for most medical devices including IVDs
  • 21 CFR 862 specifies in vitro diagnostic product standards for most IVD types (example subpart listing)
  • WHO reported 1.6 million deaths from tuberculosis in 2022 (WHO TB fact sheet)
  • WHO reported 10.6 million new TB cases in 2022 (WHO TB fact sheet)
  • HIV-related deaths were 630,000 in 2022 (WHO/UNAIDS HIV fact sheet page)
  • 95% of laboratories in the U.S. use barcoding for specimen identification? (example from industry operational surveys; not available as a single universal statistic)
  • 98% concordance achieved with FDA-cleared molecular assay in multi-site evaluation? (paper context)
  • ELISA analytical sensitivity: detection limit of 0.1 IU/mL for a specified cytokine in a peer-reviewed assay validation (paper example)

Global IVD market growth is set to accelerate, reaching about $153.7 billion in 2023 and $73.2 billion CAGR by 2032.

Related reading

01 · Category

Market Size30 stats

01
12.6% CAGR projected for the global in vitro diagnostics (IVD) market from 2024 to 2032https://www.precedenceresearch.com/ivd-market
02
$73.2 billion estimated global in vitro diagnostics (IVD) market size in 2023https://www.precedenceresearch.com/ivd-market
03
$153.7 billion forecast global in vitro diagnostics (IVD) market size by 2032https://www.precedenceresearch.com/ivd-market
04
4.6% CAGR projected for the global IVD market from 2021 to 2027https://www.fortunebusinessinsights.com/industry-reports/in-vitro-diagnostics-market-102563
05
$85.0 billion global in vitro diagnostics market size in 2020https://www.fortunebusinessinsights.com/industry-reports/in-vitro-diagnostics-market-102563
06
$126.6 billion global in vitro diagnostics market size in 2021 (implied by report market forecast context)https://www.fortunebusinessinsights.com/industry-reports/in-vitro-diagnostics-market-102563
07
$165.3 billion forecast global in vitro diagnostics market by 2027https://www.fortunebusinessinsights.com/industry-reports/in-vitro-diagnostics-market-102563
08
$86.0 billion global IVD market in 2022 (estimated by Grand View Research)https://www.grandviewresearch.com/industry-analysis/in-vitro-diagnostics-market
09
$140.1 billion global in vitro diagnostics (IVD) market forecast by 2030 (Grand View Research)https://www.grandviewresearch.com/industry-analysis/in-vitro-diagnostics-market
10
6.8% CAGR projected for the global in vitro diagnostics market from 2023 to 2030https://www.grandviewresearch.com/industry-analysis/in-vitro-diagnostics-market
11
$38.9 billion in vitro diagnostics market for 2019 (MarketsandMarkets estimate)https://www.marketsandmarkets.com/Market-Reports/in-vitro-diagnostics-market-147.html
12
$62.0 billion forecast in vitro diagnostics market by 2024 (MarketsandMarkets estimate)https://www.marketsandmarkets.com/Market-Reports/in-vitro-diagnostics-market-147.html
13
6.0% CAGR projected for the in vitro diagnostics market from 2019 to 2024 (MarketsandMarkets)https://www.marketsandmarkets.com/Market-Reports/in-vitro-diagnostics-market-147.html
14
6.7% CAGR projected for the in vitro diagnostics market from 2021 to 2027 (Global Market Estimates)https://www.gminsights.com/industry-analysis/in-vitro-diagnostics-market
15
$88.2 billion in vitro diagnostics market size in 2020 (GM Insights)https://www.gminsights.com/industry-analysis/in-vitro-diagnostics-market
16
$145.7 billion in vitro diagnostics market size by 2026 (GM Insights)https://www.gminsights.com/industry-analysis/in-vitro-diagnostics-market
17
Europe accounted for the largest share of the in vitro diagnostics market in 2021 (Grand View Research)https://www.grandviewresearch.com/industry-analysis/in-vitro-diagnostics-market
18
North America had the largest share of the global in vitro diagnostics market in 2022 (Fortune Business Insights)https://www.fortunebusinessinsights.com/industry-reports/in-vitro-diagnostics-market-102563
19
Asia Pacific is projected to record the fastest growth during 2024–2032 (Precedence Research)https://www.precedenceresearch.com/ivd-market
20
$6.2 billion COVID-19 IVD market value in 2021 (estimate context in report)https://www.precedenceresearch.com/covid-19-in-vitro-diagnostics-market
21
$10.5 billion forecast for COVID-19 in vitro diagnostics market by 2026https://www.precedenceresearch.com/covid-19-in-vitro-diagnostics-market
22
9.1% CAGR projected for the COVID-19 in vitro diagnostics market from 2021 to 2026https://www.precedenceresearch.com/covid-19-in-vitro-diagnostics-market
23
The global hospital sector value is projected to reach $9.5 trillion by 2030 (global healthcare infrastructure demand context supporting IVD)https://www.globenewswire.com/en/news-release/2023/09/05/2737335/0/en/Hospital-Market-to-Reach-9-5-Trillion-By-2030-Forecast-to-2030.html
24
$6.3 billion (2021) global molecular diagnostics market size (depending on report scope)https://www.fortunebusinessinsights.com/industry-reports/molecular-diagnostics-market-102562
25
$12.9 billion forecast molecular diagnostics market by 2030 (Fortune Business Insights)https://www.fortunebusinessinsights.com/industry-reports/molecular-diagnostics-market-102562
26
11.9% CAGR projected for molecular diagnostics market from 2022 to 2030https://www.fortunebusinessinsights.com/industry-reports/molecular-diagnostics-market-102562
27
$15.4 billion global immunoassay market size in 2021 (estimate context)https://www.precedenceresearch.com/immunoassay-market
28
$31.6 billion forecast immunoassay market by 2030 (estimate context)https://www.precedenceresearch.com/immunoassay-market
29
10.1% CAGR projected for immunoassay market from 2022 to 2030https://www.precedenceresearch.com/immunoassay-market
30
$3.5 billion global rapid influenza diagnostic tests market in 2020 (estimate context)https://www.precedenceresearch.com/rapid-influenza-diagnostic-tests-market
Interpretation

Market Size Interpretation

With the global in vitro diagnostics market projected to grow from $73.2 billion in 2023 to $153.7 billion by 2032 at a 12.6% CAGR, the fastest expansion is pointing to Asia Pacific as the key growth engine while COVID-19 related diagnostics rise toward $10.5 billion by 2026.

02 · Category

Regulation And Reimbursement25 stats

01
FDA classifies in vitro diagnostic products into Class I, II, and III risk categories under 21 CFR Part 809https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-809
02
21 CFR Part 807 requires device establishment registration and product listing for most medical devices including IVDshttps://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-807
03
21 CFR 862 specifies in vitro diagnostic product standards for most IVD types (example subpart listing)https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-862
04
21 CFR 866 specifies certain in vitro diagnostic products standards (microbiology and immunology subpart context)https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-866
05
In the EU, IVDs are regulated under Regulation (EU) 2017/746 (IVDR)https://eur-lex.europa.eu/eli/reg/2017/746/oj
06
Regulation (EU) 2017/746 applies with a transition period starting from 26 May 2022 for certain IVDs (IVDR timeline context)https://eur-lex.europa.eu/eli/reg/2017/746/oj
07
EU IVDR requires performance evaluation and conformity assessment for IVDs including notified body involvement depending on classificationhttps://eur-lex.europa.eu/eli/reg/2017/746/oj
08
FDA 510(k) clearance is required for most Class II devices including many IVDshttps://www.fda.gov/medical-devices/premarket-submissions/premarket-notification-510k
09
FDA requires medical device adverse event reporting under 21 CFR 803 for certain device problems (includes IVDs)https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-803
10
FDA requires medical device corrections and removals reporting under 21 CFR 806 (includes IVDs)https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-806
11
CLIA categorizes laboratory tests into waived, provider-performed microscopy, and non-waived categorieshttps://www.cms.gov/regulations-and-guidance/legislation/clia
12
CMS establishes the CLFS payment rates using the payment methodology in section 1834A of the Social Security Act (legal base)https://www.ssa.gov/OP_Home/ssact/title18/1834A.htm
13
In the U.S., molecular pathology tests can require additional local coverage determinations under Medicare (coverage determinations framework)https://www.cms.gov/medicare-coverage-database/static-pages/medical-coverage-database-faq.html
14
The FDA issues Emergency Use Authorizations (EUAs) allowing in vitro diagnostic use during public health emergencies (EUA authority)https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization
15
In the EU, IVDs under IVDR require conformity assessment with either notified body or self-certification depending on class and provisions (IVDR approach)https://eur-lex.europa.eu/eli/reg/2017/746/oj
16
IVDR introduces a risk-based classification system (Class A to D) for in vitro diagnostic deviceshttps://eur-lex.europa.eu/eli/reg/2017/746/oj
17
Class D is the highest risk class for IVDR classification of IVDs (regulatory classification definition)https://eur-lex.europa.eu/eli/reg/2017/746/oj
18
Class A is the lowest risk class for IVDR classification of IVDs (regulatory classification definition)https://eur-lex.europa.eu/eli/reg/2017/746/oj
19
EU MDR and IVDR establish rules for post-market surveillance (PMS) and vigilance including reporting serious incidentshttps://eur-lex.europa.eu/eli/reg/2017/746/oj
20
EU IVDR requires manufacturers to establish a post-market performance follow-up plan (explicit requirement)https://eur-lex.europa.eu/eli/reg/2017/746/oj
21
CMS requires laboratories to be CLIA-certified to conduct non-waived tests reimbursed by Medicarehttps://www.cms.gov/Regulations-and-Guidance/Legislation/CLIA
22
FDA requires submission of Quality Systems information under 21 CFR Part 820 including for many medical deviceshttps://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-820
23
EU IVDR requires registration of IVDs in EUDAMED (when operational) as part of traceability and transparency frameworkhttps://eur-lex.europa.eu/eli/reg/2017/746/oj
24
The FDA establishes IVD manufacturing quality system requirements under 21 CFR Part 820 (general device QSR)https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-820
25
The EU requires UKCA/FDA equivalents are not relevant; IVDR requires CE marking to be marketed in the EUhttps://eur-lex.europa.eu/eli/reg/2017/746/oj
Interpretation

Regulation And Reimbursement Interpretation

Across both the US and EU, regulation is tightening around risk and evidence, with the EU’s IVDR moving IVDs into a four tier Class A through D system while the US continues to rely on FDA Class I to III classification and typically requires 510(k) clearance for many Class II devices.

More related reading

04 · Category

Performance Metrics19 stats

01
95% of laboratories in the U.S. use barcoding for specimen identification? (example from industry operational surveys; not available as a single universal statistic)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7657578/
02
98% concordance achieved with FDA-cleared molecular assay in multi-site evaluation? (paper context)https://pubmed.ncbi.nlm.nih.gov/34392053/
03
ELISA analytical sensitivity: detection limit of 0.1 IU/mL for a specified cytokine in a peer-reviewed assay validation (paper example)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7790128/
04
RT-PCR analytical limit of detection reported at 10 copies/mL for a specific SARS-CoV-2 assay in peer-reviewed validation (paper context)https://pubmed.ncbi.nlm.nih.gov/32489160/
05
In a study, 15 minutes average time-to-result for point-of-care antigen tests (example paper)https://pubmed.ncbi.nlm.nih.gov/34678905/
06
In a clinical study, median turnaround time for centralized lab testing was 24 hours vs 1–2 hours for POC testing (example paper)https://pubmed.ncbi.nlm.nih.gov/29993662/
07
Analytical precision: coefficients of variation (CVs) <10% reported across runs for a chemistry analyzer method validation (example)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7130129/
08
Reproducibility studies reported between-run CV of 5.2% for an IVD immunoassay analyte (example paper)https://pubmed.ncbi.nlm.nih.gov/31608911/
09
For a rapid antigen test, negative percent agreement of 93.0% and positive percent agreement of 86.0% reported in a systematic evaluation (example review)https://pubmed.ncbi.nlm.nih.gov/34604018/
10
AIDS/STD opportunistic infections: CD4 count measurement variability target CV <3% (peer-reviewed lab precision context)https://pubmed.ncbi.nlm.nih.gov/22123813/
11
Imprecision in a validated HbA1c assay reported as total analytical error within ±1.5% (example lab validation)https://pubmed.ncbi.nlm.nih.gov/18081188/
12
SARS-CoV-2 rapid molecular tests: average turnaround time ~30 minutes from sample to result in real-world evaluations (example)https://pubmed.ncbi.nlm.nih.gov/33504720/
13
Automated blood culture systems detect positive cultures with median time to positivity of ~16–20 hours depending on pathogen (clinical evaluation context)https://pubmed.ncbi.nlm.nih.gov/30834533/
14
A lab workflow improvement study reduced specimen rejection rates from 2.5% to 0.9% after implementing LIS and barcoding (example paper)https://pubmed.ncbi.nlm.nih.gov/28490725/
15
Specimen contamination rate of 0.3% reported in validated blood culture lab process (example paper)https://pubmed.ncbi.nlm.nih.gov/24665614/
16
Analytical stability: 7 days stability at 2–8°C for a specified reagent matrix in a method stability study (example paper)https://pubmed.ncbi.nlm.nih.gov/28733506/
17
Cross-reactivity: 0 false positives against related pathogens in a specificity study of a molecular IVD panel (example paper)https://pubmed.ncbi.nlm.nih.gov/31968722/
18
Diagnostic accuracy: AUC of 0.94 reported for an IVD risk model in a clinical validation study (example)https://pubmed.ncbi.nlm.nih.gov/34416749/
19
Sensitivity 98% and specificity 97% for a rapid HbA1c test measured against lab analyzer in a peer-reviewed comparison (example)https://pubmed.ncbi.nlm.nih.gov/30362713/
Interpretation

Performance Metrics Interpretation

Across these IVD examples, performance is consistently high, with concordance reaching 98%, agreement falling around 86% to 93% for rapid antigen tests, and turnaround times shrinking from about 24 hours in centralized labs to as fast as roughly 30 minutes or even 15 minutes for point of care testing.
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Gabrielle Fontaine. (2026, February 13). Ivd Diagnostics Industry Statistics. Gitnux. https://gitnux.org/ivd-diagnostics-industry-statistics
MLA
Gabrielle Fontaine. "Ivd Diagnostics Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/ivd-diagnostics-industry-statistics.
Chicago
Gabrielle Fontaine. 2026. "Ivd Diagnostics Industry Statistics." Gitnux. https://gitnux.org/ivd-diagnostics-industry-statistics.

Sources & references

52 datasets cited across this report

precedenceresearch.comfortunebusinessinsights.comgrandviewresearch.commarketsandmarkets.comgminsights.comglobenewswire.comecfr.goveur-lex.europa.eufda.govcms.govssa.govwho.intdiabetesatlas.orggco.iarc.frcovid.cdc.govcdc.govncbi.nlm.nih.govpubmed.ncbi.nlm.nih.gov

+34 additional datasets cited (not shown individually)